CAJ | 학술논문

目的探讨左旋门冬酰胺酶(L-Asp)联合DICE方案治疗复发难治性非霍奇金淋巴瘤(NHL)的疗效和安全性.方法 31例复发难治性NHL患者接受L-Asp联合DICE方案治疗,每位患者计划接受2～6个周期化疗.结果在所有可评估的31例患者中,11例(35.5％)完全缓解(CR),14例(45.2％)部分缓解(PR),2例稳定,总有效(CR+PR)率为80.7％.有效患者中位生存期为8个月(2～30个月).全组患者预计1年生存率为43.3％,2年生存率为32.5％.主要不良反应为骨髓抑制、消化道反应、变态反应和水肿.治疗期间未观察到治疗相关性死亡.结论 L-Asp联合DICE方案治疗复发难治性NHL是有效和安全的.
목적 탐토좌선문동선알매(L-Asp)연합DICE방안치료복발난치성비곽기금림파류(NHL)적료효화안전성.방법 31례복발난치성NHL환자접수L-Asp연합DICE방안치료,매위환자계화접수2～6개주기화료.결과 재소유가평고적31례환자중,11례(35.5％)완전완해(CR),14례(45.2％)부분완해(PR),2례은정,총유효(CR+PR)솔위80.7％.유효환자중위생존기위8개월(2～30개월).전조환자예계1년생존솔위43.3％,2년생존솔위32.5％.주요불량반응위골수억제、소화도반응、변태반응화수종.치료기간미관찰도치료상관성사망.결론 L-Asp연합DICE방안치료복발난치성NHL시유효화안전적.
Objective To observe the efficacy and adverse events of L-asparaginasum plus DICE regimen in the treatment of relapsed and refractory non-Hodgkin's lymphoma (NHL). Methods Thirty-one patients with relapsed and refractory NHL were treated with L-asparaginasum plus DICE regimen. Each patient was scheduled to receive 2 to 6 cycles.Results Among the 31 assessable patients,11 (35.5 ％) achieved a complete remission (CR),14(45.2 ％) got a partial remission (PR),2 were stable,4 were progressive.The overall response (CR + PR) rate was 80.7 ％.The median survival was 8 months (rang:2-38 months).The 1-year survival rate was 43.3 ％,the 2-year survival rate was 32.5 ％.The main adverse events were myelosuppression,digestive tract reaction,allergy and edema.No treatment-related death was observed.Conclusion The L-asparaginasum plus DICE regimen is effective and safe for the relapsed and refractory NHL.